Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
Parekh
Chintan
C
Division of Pediatric Hematology Oncology, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, MS# 54, Los Angeles, CA 90027, USA. cparekh@chla.usc.edu
Jubran
Rima
R
Erdreich-Epstein
Anat
A
Panigrahy
Ashok
A
Bluml
Stefan
S
Finlay
Jonathan
J
Dhall
Girish
G
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002794:Choline / Q000378:metabolism; D018450:Disease Progression; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality; D013997:Time Factors; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D002794:Choline